Prof. Yan Wang 王艳
Chief Physician, Professor
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and biological therapy for lung cancer, breast cancer, lymphoma, liver cancer, gastric cancer, colorectal cancer, multiple myeloma, and malignant pleural or ascitic fluid.
Dr. Wang is Chief of Internal Medicine Department 5 at Harbin Medical University Cancer Hospital. Dr. Wang earned a medical degree from Harbin Medical University in 1985, a master’s in 1999, and a PhD in Integrated Traditional Chinese and Western Medicine in 2008. With over 20 years of experience in oncology chemotherapy, Dr. Wang conducts research on lung, breast, gastric, and colorectal cancers.
Professional roles
- Executive Committee Member, Clinical Oncology Collaboration Professional Committee, China Anti-Cancer Association
- Member, Lung Cancer Professional Committee, Heilongjiang Anti-Cancer Association
- Member, Chemotherapy Professional Committee, Heilongjiang Anti-Cancer Association
- Member, Esophageal Cancer Professional Committee, Heilongjiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Yan). Papers usually list the name as Yan Wang or Wang Y.
Selected publications
90 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Mol Histol, 2026 (senior author): TET1-mediated DNA demethylation and transcription activation of MRPS17 induces lung adenocarcinoma through PI3K-AKT-mTOR pathway. PubMed 42665721
- Br J Pharmacol, 2026 (first author): Clu(+) transitional alveolar epithelial cells promote lung injury repair and fibrosis progression. PubMed 41797553
- NPJ Precis Oncol, 2025 (senior author): Spatial transcriptomics reveals macrophage domestication by epithelial cells promotes immunotherapy resistance in small cell lung cancer. PubMed 40702109
- Mol Biotechnol, 2025 (senior author): Omaveloxolone Prevents Polystyrene Microplastic-Induced Ovarian Granulosa Cell Apoptosis via the Keap1/Nrf2/HO-1 Pathway in Rats. PubMed 38775936
- BMC Cancer, 2024 (senior author): Clinical significance of the combined systemic immune-inflammatory index and prognostic nutritional index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy. PubMed 39719567
- Biochem Biophys Res Commun, 2024 (senior author): Bufalin: A promising therapeutic drug against the cisplatin-resistance of ovarian cancer by targeting the USP36/c-Myc axis. PubMed 39067250
- Heliyon, 2024 (first author): Analysis and study of the mechanism of narcotic addiction and withdrawal. PubMed 38449641
- Heliyon, 2023 (first author): Prediction of immune and targeted drug efficacy in pain-related risk subtypes for bladder cancer patients. PubMed 37455996
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion